USD
  • USD
  • EUR
  • GBP

FREE SHIPPING in UK for orders over £75!

lasers for BPH (Benign prostatic hyperplasia ) /benign enlargement of the prostate

Weight:

Collections: All products, Surgical Medical Equipment

Product type: laser equipment

Vendor: GA laser

Availability:

$38,500.00

INTRODUCTION

Wavelength

980nm

980nm+1470nm

Maximum Power

150W/200W

150W+40W

Operation Mode

CW and pulsed

Pulse Duration

100ms-1s

Repetition Rate

0.5Hz-50Hz

Pilot Beam

Red Diode Laser Of 650nm, Power<5mW

Control Mode

Touch Screen

Dimension

300(H)*545(W)*540(L) mm

Lifetime

Over 20000 hrs

Warranty

12 months free warranty, 5 years technical

Weight

support 50Kg

Packing

Carry case with carton

Benign prostatic hyperplasia (BPH), also called benign enlargement of the prostate (BEP), adenofibromyomatous hyperplasia and benign prostatic hypertrophy (technically incorrect usage), is an increase in size of the prostate.

BPH involves hyperplasia of prostatic stromal and epithelial cells, resulting in the formation of large, fairly discrete nodules in the periurethral region of the prostate. When sufficiently large, the nodules compress the urethral canal to cause partial, or sometimes virtually complete, obstruction of the urethra, which interferes with the normal flow of urine. It leads to symptoms of urinary hesitancy, frequent urination, increased risk of urinary tract infections, urinary retention, or contribute to or cause insomnia. Although prostate specific antigen levels may be elevated in these patients because of increased organ volume and inflammation due to urinary tract infections, BPH does not lead to cancer or increase the risk of cancer.

BPH involves hyperplasia (an increase in the number of cells) rather than hypertrophy (a growth in the size of individual cells), but the two terms are often used interchangeably, even amongst urologists.

Adenomatous prostatic growth is believed to begin at approximately age 30 years. An estimated 50% of men have histologic evidence of BPH by age 50 years and 75% by age 80 years; in 40–50% of these men, BPH becomes clinically significant.

PRINCIPLE OF TREATMENT

The treatment commences by inserting the Cystoscope containing our new BPH probe through the urethra. The head of the bare fiber is pushed out of the probe. The dual laser of 980nm and 1470nm is discharged fromthe probe head.

The operator steers the probe, rotating it to ablate the tissue in a circular motion.The funnel grows larger step by step and the BPH probe is withdrawn from the prostate at the end. Urine can once again flow off freely.

Since the wavelength is highly absorbed by water and haemoglobin , so the vaporization and coagulation to the prostate tissue can be realised simultaneously. The high power laser energy is transmited by the special side fiber through the endoscopy in visible , it’s currently the most advanced minimally invasive treatment method. Compared to the traditional surgery, this procedure is a low- trauma, low-pain, low-risk, comfortable and fast recovery .